Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by Dibah420on Mar 18, 2022 12:30pm
234 Views
Post# 34525673

Mitts vs the shorts

Mitts vs the shortsRemember black mamba, seeking alpha, muddy waters, carson block etc etc?  Here's an interesting piece:

How a Columbia professor became the scourge of activist short sellers

Undated handout photo of Joshua Mitts
 
 

By Chris Prentice

WASHINGTON (Reuters) - You may not have heard of Joshua Mitts, a young Columbia University professor who is making some powerful enemies on Wall Street.

The 36-year-old securities law specialist has become an increasingly influential figure in the hot debate over activist short selling since publishing a 2018 analysis of trading data that suggested some players were manipulating the market.

Interviews with 12 people familiar with his work and career, including Mitts himself and some of his toughest critics, shed light on how an academic little known outside his field just a few years ago has since taken center stage in the ugly feud between short sellers and the companies they target.

 

That struggle has sparked a sprawling probe by the U.S. Department of Justice and the Securities and Exchange Commission (SEC) into suspected trading manipulation by short sellers and hedge funds.

Activist short sellers like Muddy Waters' Carson Block bet against public companies they deem over-valued and then publish their investment thesis. They say their work aids market efficiency and dispute Mitts' analysis as flawed.

Nonetheless the interviews, which detail Mitts' contacts with U.S. authorities, show the professor and his work have played a significant role in the federal probes.

"One reason the work really resonated was it took a large sample and showed there was evidence for what companies were saying: that there was potential abuse," said Peter Molk, a law professor at the University of Florida.

Mitts declined to comment on his work for the Justice Department beyond pointing to a statement on his resume that he has "extensive experience supporting" the agency. He defended his research and said he wanted to be objective and is not opposed to short selling.

"Not only is short selling not illegal, it's important to have bears," he said.

Spokespeople for the Justice Department and the SEC, the main stock market regulator, declined to comment.


<< Previous
Bullboard Posts
Next >>